VA Office of Research and Development

DelveInsight's 'Spinal Cord Injury Pipeline Insight, 2024' report details 35+ therapies in development by 35+ companies, including Athersys, Olatec Therapeutics, and AbbVie, focusing on mechanism of action, clinical trials, and market prospects. Key therapies include Allogeneic stem cell therapy, OLT1177, and Elezanumab, with ongoing trials and potential market impact. The report covers pre-clinical to marketed phases, regulatory approvals, and market dynamics.